Literature DB >> 28108047

The diagnosis and treatment of hepatocellular carcinoma.

Justin Hartke1, Matthew Johnson2, Marwan Ghabril3.   

Abstract

Hepatocellular carcinoma is a leading cancer worldwide. Its incidence is increasing, and is closely related to advanced liver disease. Cirrhosis represents the greatest risk factor for this malignancy, and is the main indication for screening and surveillance. The diagnosis of hepatocellular carcinoma can frequently, and uniquely, be made on characteristic multiphase contrast based cross-sectional imaging rather than strict need for tissue sampling. Despite advances in medical, locoregional and surgical therapies, hepatocellular carcinoma remains one of the most common causes of cancer-related death globally. In this review, current approaches to management of hepatocellular carcinoma are discussed, which incorporate both tumor and patient factors. The salient considerations in surgical (resection, liver transplantation), locoregional (ablation and embolic therapies) and medical therapies are highlighted.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer system; Cirrhosis; Diagnosis; Liver transplantation; Locoregional therapy; Resection; Screening; Treatment

Mesh:

Year:  2016        PMID: 28108047     DOI: 10.1053/j.semdp.2016.12.011

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  195 in total

1.  Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma.

Authors:  Wanli Yang; Liaoran Niu; Xinhui Zhao; Lili Duan; Yiding Li; Xiaoqian Wang; Yujie Zhang; Wei Zhou; Jinqiang Liu; Qingchuan Zhao; Yu Han; Daiming Fan; Liu Hong
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  Long noncoding RNA SNHG14 facilitates hepatocellular carcinoma progression through regulating miR-4673/SOCS1.

Authors:  Jian Pu; Huamei Wei; Chuan Tan; Bangze Qin; Ya Zhang; Anmin Wang; Jianchu Wang
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 3.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

4.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

5.  Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes.

Authors:  Seh-Hoon Oh; Marzena Swiderska-Syn; Mark L Jewell; Richard T Premont; Anna Mae Diehl
Journal:  J Hepatol       Date:  2018-05-23       Impact factor: 25.083

6.  Study on the diagnosis of small hepatocellular carcinoma caused by hepatitis B cirrhosis via multi-slice spiral CT and MRI.

Authors:  Mei Wang; Congxin Wei; Zhaojuan Shi; Jianzhong Zhu
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

7.  LncRNA FLJ33360 accelerates the metastasis in hepatocellular carcinoma by targeting miRNA-140/MMP9 axis.

Authors:  Zhenhui Lu; Yingzi Yu; Xiangchun Ding; Dong Jin; Genwang Wang; Yu Zhou; Yongzhao Zhu; Li Na; Yaqin He; Qi Wang
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

8.  CT Image-Based Texture Analysis to Predict Microvascular Invasion in Primary Hepatocellular Carcinoma.

Authors:  Yueming Li; Xuru Xu; Shuping Weng; Chuan Yan; Jianwei Chen; Rongping Ye
Journal:  J Digit Imaging       Date:  2020-09-23       Impact factor: 4.056

9.  LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.

Authors:  Yongxian Cao; Feng Zhang; Haotian Wang; Chunhua Bi; Jinpeng Cui; Fenghai Liu; Huazheng Pan
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

10.  Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.

Authors:  Yun Bian; Dong Guo
Journal:  Drug Des Devel Ther       Date:  2020-02-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.